Filing Flows › Health Care › Alector (ALEC)
Alector (ALEC) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Alector (ALEC) Q3 2026 earnings results →
Q3 2026 Revenue up 4896% year over year to $163M · 77¢ of every $1 of revenue kept as net profit · operating margin 76.0%
Alector made $163M in Q3 2026 (50× Y/Y). Operating margin 76.0%, net earnings $125M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $162.9M in Q3 2026, up 4896% year over year and up 4806% from the previous quarter.
Operating profit was $123.8M, a 76.0% margin (up 1229.7 points year over year). Total costs fell 5% while revenue rose 4896%. Net earnings were $124.6M. The effective tax rate was 0.0%.
Operating cash flow was −$24.2M. Non-cash charges added back $1.0M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $151.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $163M | 50× | 76.0% | $125M | −$24.2M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $3.3M | -58% | -734.7% | −$23.0M | −$34.2M |
| Q1 2026 | 10-Q | May 7, 2026 | $1.0M | -72% | n/m | −$22.9M | −$49.8M |
| Q4 2025 | 10-K | Feb 25, 2026 | $6.2M | -88% | -634.4% | −$37.3M | −$41.7M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $3.3M | -79% | n/m | −$34.7M | −$32.5M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $7.9M | -48% | -433.6% | −$30.5M | −$49.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $3.7M | -77% | n/m | −$40.5M | −$60.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Alector
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs.
In its own words, from its 8-K, filed Oct 5, 2026.
Alector against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 50× against the peers' median +29%. Operating margin: 76.0% against the peers' median 40.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ALEC Alector | Q3 2026 | $163M | 50× | 76.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Alector 10-Q on SEC EDGAR · CIK 1653087 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns ALEC and who is buying
More on ALEC
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results